A citation-based method for searching scientific literature

Amit Bardia, Mabel Wai, Manuel L Fontes. Curr Opin Anaesthesiol 2019
Times Cited: 7







List of co-cited articles
25 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Venkatesan Thiruvenkatarajan, Emily Jane Meyer, Nagesh Nanjappa, Roelof M Van Wijk, David Jesudason. Br J Anaesth 2019
16
71

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Susan J Bersoff-Matcha, Christine Chamberlain, Christian Cao, Cindy Kortepeter, William H Chong. Ann Intern Med 2019
64
42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
42


Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery.
Anna Frisch, Prakash Chandra, Dawn Smiley, Limin Peng, Monica Rizzo, Chelsea Gatcliffe, Megan Hudson, Jose Mendoza, Rachel Johnson, Erica Lin,[...]. Diabetes Care 2010
269
42

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
28

Hypoglycemia and risk of death in critically ill patients.
Simon Finfer, Bette Liu, Dean R Chittock, Robyn Norton, John A Myburgh, Colin McArthur, Imogen Mitchell, Denise Foster, Vinay Dhingra, William R Henderson,[...]. N Engl J Med 2012
481
28

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
58
28


SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Kelly R Burke, Christine A Schumacher, Spencer E Harpe. Pharmacotherapy 2017
70
28

The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
Theocharis Koufakis, Omar G Mustafa, Ramzi A Ajjan, Xavier Garcia-Moll, Pantelis Zebekakis, George Dimitriadis, Kalliopi Kotsa. J Clin Pharm Ther 2020
8
28


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
28


Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery).
Guillermo E Umpierrez, Dawn Smiley, Sol Jacobs, Limin Peng, Angel Temponi, Patrick Mulligan, Denise Umpierrez, Christopher Newton, Darin Olson, Monica Rizzo. Diabetes Care 2011
334
28

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Francisco J Pasquel, Roma Gianchandani, Daniel J Rubin, Kathleen M Dungan, Isabel Anzola, Patricia C Gomez, Limin Peng, Israel Hodish, Tim Bodnar, David Wesorick,[...]. Lancet Diabetes Endocrinol 2017
72
28


Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.
Priyathama Vellanki, Neda Rasouli, David Baldwin, Sara Alexanian, Isabel Anzola, Maria Urrutia, Saumeth Cardona, Limin Peng, Francisco J Pasquel, Guillermo E Umpierrez. Diabetes Obes Metab 2019
20
28

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
97
28

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter. Cochrane Database Syst Rev 2010
270
28

Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes.
Meera Kotagal, Rebecca G Symons, Irl B Hirsch, Guillermo E Umpierrez, E Patchen Dellinger, Ellen T Farrokhi, David R Flum. Ann Surg 2015
140
28


SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Ronald M Goldenberg, Lori D Berard, Alice Y Y Cheng, Jeremy D Gilbert, Subodh Verma, Vincent C Woo, Jean-François Yale. Clin Ther 2016
73
28

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
645
28

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
28

Euglycemic diabetic ketoacidosis.
Leonid Barski, Tamar Eshkoli, Evgenia Brandstaetter, Alan Jotkowitz. Eur J Intern Med 2019
20
14

EMPA-REG OUTCOME: The Cardiologist's Point of View.
Son V Pham, Robert Chilton. Am J Med 2017
7
14

Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Aaron Y Kluger, Kristen M Tecson, Andy Y Lee, Edgar V Lerma, Janani Rangaswami, Norman E Lepor, Michael E Cobble, Peter A McCullough. Cardiovasc Diabetol 2019
34
14

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
185
14


Review of Evidence for Adult Diabetic Ketoacidosis Management Protocols.
Tara T T Tran, Anthony Pease, Anna J Wood, Jeffrey D Zajac, Johan Mårtensson, Rinaldo Bellomo, Elif I I Ekinci. Front Endocrinol (Lausanne) 2017
22
14


Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series.
Gina McLachlan, Claire Keith, Albert Frauman. Med J Aust 2019
2
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
753
14

Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes.
Silvia González Sanchidrián, Juan Ramón Gómez-Martino Arroyo, Pedro Jesús Labrador Gómez. Med Clin (Barc) 2017
2
50

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
68
14

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.
Majken Linnemann Jensen, Frederik Persson, Gregers S Andersen, Martin Ridderstråle, John J Nolan, Bendix Carstensen, Marit E Jørgensen. Diabetes Care 2017
22
14


Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Michelle Isaacs, Katherine T Tonks, Jerry R Greenfield. Intern Med J 2017
11
14


SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
233
14

Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.
Devon J Pace, Katerina Dukleska, Samantha Phillips, Vanessa Gleason, Charles J Yeo. J Pancreat Cancer 2018
6
16

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N Engl J Med 2017
115
14


Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.
D Taylor Gammons, Francis L Counselman. Clin Pract Cases Emerg Med 2018
3
33

Diabetic Ketoacidosis Post Bariatric Surgery.
Ivania M Rizo, Caroline M Apovian. Front Endocrinol (Lausanne) 2019
3
33

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw,[...]. Ann N Y Acad Sci 2015
58
14



Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy.
Eleni Papadokostaki, Evangelos Liberopoulos. Case Rep Endocrinol 2019
2
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.